Drug Trial Radar · NCT02384941
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
Last checked: Nov 20, 2026Latest source record: Feb 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
793
Actual
Start
Mar 2015
Primary completion
Sep 2016
Study completion Feb 2017
Sponsor
- Lead sponsor
- Lexicon PharmaceuticalsIndustry
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Mar 10, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study was intended to demonstrate superiority of either sotagliflozin high dose or low dose versus placebo on glycosylated hemoglobin A1C (A1C) reduction at Week 24 when used as an adjunct in adult participants with type 1 diabetes mellitus (T1D) who have inadequate glycemic control with insulin therapy.
Conditions
- Type 1 Diabetes Mellitus
Interventions
PlaceboDrug
Placebo once daily, before first meal of the day.
SotagliflozinDrug
Sotagliflozin once daily, before first meal of the day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in A1C at Week 24Time frame: Baseline to Week 24
Locations
75 sites in 2 countries. Site status is shown where the registry gives one.
Lexicon Investigational Site
Birmingham, Alabama
Lexicon Investigational Site
Little Rock, Arkansas
Lexicon Investigational Site
Escondido, California
Lexicon Investigational Site
Greenbrae, California
Lexicon Investigational Site
Huntington Beach, California
Lexicon Investigational Site
La Jolla, California
Lexicon Investigational Site
Los Angeles, California
Lexicon Investigational Site
Orange, California
Lexicon Investigational Site
Palm Springs, California
Lexicon Investigational Site
San Mateo, California
Lexicon Investigational Site
Tarzana, California
Lexicon Investigational Site
Tustin, California
Lexicon Investigational Site
Walnut Creek, California
Lexicon Investigational Site
Aurora, Colorado
Lexicon Investigational Site
Longmont, Colorado
Lexicon Investigational Site
Fleming Island, Florida
Lexicon Investigational Site
Jacksonville, Florida
Lexicon Investigational Site
Jacksonville, Florida
Lexicon Investigational Site
New Port Richey, Florida
Lexicon Investigational Site
Ormond Beach, Florida
Lexicon Investigational Site
West Palm Beach, Florida
Lexicon Investigational Site
Atlanta, Georgia
Lexicon Investigational Site
Lawrenceville, Georgia
Lexicon Investigational Site
Roswell, Georgia
Lexicon Investigational Site
Honolulu, Hawaii
Lexicon Investigational Site
Crystal Lake, Illinois
Lexicon Investigational Site
Elgin, Illinois
Lexicon Investigational Site
Springfield, Illinois
Lexicon Investigational Site
Topeka, Kansas
Lexicon Investigational Site
Lexington, Kentucky
Lexicon Investigational Site
Bangor, Maine
Lexicon Investigational Site
Baltimore, Maryland
Lexicon Investigational Site
Boston, Massachusetts
Lexicon Investigational Site
Detroit, Michigan
Lexicon Investigational Site
Chesterfield, Missouri
Lexicon Investigational Site
St Louis, Missouri
Lexicon Investigational Site
Omaha, Nebraska
Lexicon Investigational Site
Henderson, Nevada
Lexicon Investigational Site
Las Vegas, Nevada
Lexicon Investigational Site
Albany, New York
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.